A detailed history of Crocodile Capital Partners Gmb H transactions in Bio N Tech Se stock. As of the latest transaction made, Crocodile Capital Partners Gmb H holds 29,586 shares of BNTX stock, worth $3.32 Million. This represents 3.78% of its overall portfolio holdings.

Number of Shares
29,586
Previous 29,586 -0.0%
Holding current value
$3.32 Million
Previous $2.73 Billion 12.89%
% of portfolio
3.78%
Previous 3.76%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 10, 2023

BUY
$102.58 - $129.66 $3.03 Million - $3.84 Million
29,586 New
29,586 $3.19 Billion

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Crocodile Capital Partners Gmb H Portfolio

Follow Crocodile Capital Partners Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crocodile Capital Partners Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Crocodile Capital Partners Gmb H with notifications on news.